Septerna Stock News

SOUTH SAN FRANCISCO, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the dosing of the first participants in its Phase 1 clinical trial of SEP-631, a selective oral small molecule Mas-related G protein-coupled receptor X2 (MRGPRX2) negative al...

Advancing Selection of Next-Generation Oral Small Molecule PTH1R Agonist for Clinical Development Initiating Phase 1 Trial for SEP-631, MRGPRX2 NAM Program, for Mast Cell Diseases Updated Cash Runway Expected to Support Operating Plans at Least into 2029 SOUTH SAN FRANCISCO, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of ...

SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that Jeffrey Finer, M.D.

Persistent volatility has plagued the S&P 500 for much of 2025, prompting widespread caution among many investors amid the uncertainties of trade battles, tariffs, domestic policy, and more. Investors might remember that many of the biggest rallies take place during these volatile periods, and there may be potential to win big gains for those with at least a moderate tolerance for risk.

Septerna's partnership with Novo Nordisk is a strong endorsement, but the $195m upfront is modest (by Big Pharma standards) and milestone payments are not guaranteed. The company's innovative GPCR platform and deep pipeline are promising, yet early clinical setbacks and fierce competition raise execution risks. Septerna's cash position is solid for now, but future clinical expenses may require ...

Septerna's partnership with Novo Nordisk validates its GPCR drug discovery platform and injects $195 million in upfront cash, with potential for more than $2 billion in milestone payments. The stock trades below net cash even after the Novo deal, offering investors a rare opportunity to buy the pipeline and partnership essentially for free. NVO will cover R&D costs for four programs, extending ...

Announced Global Collaboration with Novo Nordisk to Develop Oral Small Molecules for Metabolic Diseases with Over $2.2 Billion in Potential Milestone Payments

Septerna (NASDAQ:SEPN) shares surged almost 50% after the announcement of an exclusive global collaboration and license deal with Novo Nordisk (NYSE:NVO) to develop oral small molecule medicines targeting obesity and other cardiometabolic diseases. The partnership brings together Septerna's expertise in G protein-coupled receptor (GPCR) drug discovery with Nono Nordisk's established obesity and...